ARTICLE | Clinical News
FDA wants more studies by Pozen
January 26, 2001 8:00 AM UTC
The FDA requested additional animal carcinogenicity studies of POZN's MT 100 combination of metoclopramide and naproxen to treat migraine, which is in Phase III trials. POZN had requested a complete w...